Molnupiravir, Paxlovid, and AZD7442 have shown promise in Phase 3 trials.
Molnupiravir, Paxlovid, and AZD7442 have shown promise in Phase 3 trials.
Phase 3 clinical trials for this non-opioid drug demonstrate significant reductions in pain for osteoarthritis and chronic low-back pain.
Phase 2/3 clinical trial results for Korsuva demonstrate pain relief with fewer side effects.
